Abstract
One of the most rapidly advancing areas of gene therapy is vector development. For the majority of gene therapy procedures, efficient and selective transduction would provide safe and more effective treatments at optimal vector doses. Advances in vector targeting strategies have been rapid within the field of DNA-based viruses, particularly adenovirus (Ad) and more recently adeno-associated virus (AAV) based vectors. Vector targeting at the level of virus: cell interaction can be achieved using both non-genetic and genetic methodology. Non-genetic approaches typically utilise bispecific antibodies that both neutralise wild-type virus tropism and provide a new cell binding capacity. For genetic targeting strategies, the virus capsid can be engineered to express foreign ligands that target selected receptors in the absence or presence of additional modification to ablate the virusnatural tropism. This review covers technological advances that have led to targeting of Ad and AAV and highlights the potential for these ‘designer’ viruses for future gene-based therapeutics.
Keywords: Tropism-Modified Adenoviral, Adeno-Associated, Viral Vectors, Gene Therapy, PSEUDOTYPING, TROPISM EXPANSION, TARGETING AAV
Current Gene Therapy
Title: Tropism-Modified Adenoviral and Adeno-Associated Viral Vectors for Gene Therapy
Volume: 2 Issue: 3
Author(s): Stuart A. Nicklin and Andrew H. Baker
Affiliation:
Keywords: Tropism-Modified Adenoviral, Adeno-Associated, Viral Vectors, Gene Therapy, PSEUDOTYPING, TROPISM EXPANSION, TARGETING AAV
Abstract: One of the most rapidly advancing areas of gene therapy is vector development. For the majority of gene therapy procedures, efficient and selective transduction would provide safe and more effective treatments at optimal vector doses. Advances in vector targeting strategies have been rapid within the field of DNA-based viruses, particularly adenovirus (Ad) and more recently adeno-associated virus (AAV) based vectors. Vector targeting at the level of virus: cell interaction can be achieved using both non-genetic and genetic methodology. Non-genetic approaches typically utilise bispecific antibodies that both neutralise wild-type virus tropism and provide a new cell binding capacity. For genetic targeting strategies, the virus capsid can be engineered to express foreign ligands that target selected receptors in the absence or presence of additional modification to ablate the virusnatural tropism. This review covers technological advances that have led to targeting of Ad and AAV and highlights the potential for these ‘designer’ viruses for future gene-based therapeutics.
Export Options
About this article
Cite this article as:
Nicklin A. Stuart and Baker H. Andrew, Tropism-Modified Adenoviral and Adeno-Associated Viral Vectors for Gene Therapy, Current Gene Therapy 2002; 2 (3) . https://dx.doi.org/10.2174/1566523023347797
DOI https://dx.doi.org/10.2174/1566523023347797 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Melatonin Signaling in Health and Disease
Melatonin regulates a multitude of physiological functions, including circadian rhythms, acting as a scavenger of free radicals, an anti-inflammatory agent, a modulator of mitochondrial homeostasis, an antioxidant, and an enhancer of nitric oxide bioavailability. AANAT is the rate-limiting enzyme responsible for converting serotonin to NAS, further converted to melatonin by ...read more
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-Cancer Therapy: Targeting the Mevalonate Pathway
Current Cancer Drug Targets Drug Repositioning for Treatment of Movement Disorders: From Serendipity to Rational Discovery Strategies
Current Topics in Medicinal Chemistry Mode of Action of Long-Term Low-Dose Macrolide Therapy for Chronic Sinusitis in the Light of Neutrophil Recruitment
Current Drug Targets - Inflammation & Allergy Altering the Tropism of Lentiviral Vectors through Pseudotyping
Current Gene Therapy The Role of the Endocannabinoid System in Alzheimers Disease: Facts and Hypotheses
Current Pharmaceutical Design Azole Antimycotics - A Highway to New Drugs or a Dead End?
Current Medicinal Chemistry Overview of the Structure and Function of Protein Kinases
Current Enzyme Inhibition Protein Tyrosine Nitration in Lung Cancer: Current Research Status and Future Perspectives
Current Medicinal Chemistry Cannabinoids and Cancer
Mini-Reviews in Medicinal Chemistry The Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Treatment of Solid Tumors
Current Cancer Therapy Reviews Anticancer Vitamin K3 Analogs: A Review
Anti-Cancer Agents in Medicinal Chemistry Editorial from Guest Editor (DNA Methylation: A Target for Current and Future Therapies?)
Epigenetic Diagnosis & Therapy (Discontinued) Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry The Urokinase Receptor as a Potential Target in Cancer Therapy
Current Pharmaceutical Design Peptide Prodrugs for the Treatment of CNS Disorders: A Perspective for New Drugs
Current Medicinal Chemistry Neuropharmacology of the Endocannabinoid Signaling System-Molecular Mechanisms, Biological Actions and Synaptic Plasticity
Current Neuropharmacology Apoptosis Pathways and Neuroblastoma Therapy
Current Pharmaceutical Design Oncolytic Viruses for Induction of Anti-Tumor Immunity
Current Pharmaceutical Biotechnology Editorial
Recent Patents on Inflammation & Allergy Drug Discovery The Role of Protein Kinase C-alpha (PKC-α) in Cancer and its Modulation by the Novel PKC-α-Specific Inhibitor Aprinocarsen
Current Pharmaceutical Design